Trial Profile
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment With Two Different Doses of Recombinant Factor XIII Following Cardiopulmonary Bypass Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Catridecacog (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 06 Oct 2014 New trial record